Protein

EQS-News: Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies

Retrieved on: 
Wednesday, April 10, 2024

EQS-News: Secarna Pharmaceuticals GmbH & Co. KG

Key Points: 
  • EQS-News: Secarna Pharmaceuticals GmbH & Co. KG
    The issuer is solely responsible for the content of this announcement.
  • Dallas, TX, USA and Martinsried, Germany, March 20, 2024 – Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
  • “Collaborating with Secarna allows us to develop an innovative implant that has the potential to significantly change the way disease-modifying ASO therapies are administered,” said Cyonna Holmes, Global Business Strategy Leader for Ophthalmology and RNA at Celanese.
  • “We are looking forward to partnering with Celanese to combine our industry-leading ASO platform with their VitalDose® drug delivery technology,” said Konstantin Petropoulos, CBO of Secarna Pharmaceuticals.

Sharon Personal Care to Introduce Innovative New Haircare Technology at in-cosmetics 2024

Retrieved on: 
Thursday, April 4, 2024

SharoHYAL(R) Moringa is proven to improve hair elasticity, resilience by 6%; moisturization by 45%

Key Points: 
  • Trezzo sull'Adda, Italy--(Newsfile Corp. - April 4, 2024) - Sharon Personal Care, a global supplier of innovative, environmentally friendly ingredient solutions for a broad range of personal care products, will introduce SharoHYAL® Moringa, an innovative hair restoration solution, at in-cosmetics 2024, taking place April 15-20 in Paris.
  • In clinical testing, SharoHYAL Moringa has proven to increase hair moisturization by 45% after only one treatment.
  • Sharon Personal Care will be providing demonstrations of SharoHYAL Moringa throughout in-cosmetics 2024 in their booth, 1K70.
  • Sharon will also host a press conference on Wednesday, April 17 at 9:00 a.m. to introduce a groundbreaking multifunctional preservation system.

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Retrieved on: 
Tuesday, April 9, 2024

ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.

Key Points: 
  • ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.
  • ALS is a fatal neurodegenerative disease of motor neurons.
  • “Publication of these data underscores the connection of misfolded proteins and ALS and supports targeting our TDP-43-specific epitope with PMN267 as a potential therapeutic approach,” stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
  • “PMN267 is advancing through preclinical development and is showing promise as a potential treatment for ALS.

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs

Retrieved on: 
Tuesday, April 9, 2024

CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced new preclinical data for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, selective CBP degrader, and selective EP300 degrader programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting. Foghorn management will hold a conference call and webcast today at 5 p.m. ET to review important pipeline updates.

Key Points: 
  • “Notably, our first-in-class BRM selective inhibitor FHD-909 has demonstrated favorable tolerability and encouraging dose-dependent single agent activity in preclinical models of BRG1 mutated tumors.
  • Additionally, we are applying our long-acting formulation capabilities to our degrader programs, which further enhances the clinical potential of these drug candidates.
  • However, the ATPase domains of BRM and BRG1are 92% identical which has made identifying a selective BRM inhibitor challenging.
  • Attempts to selectively inhibit CBP or EP300 individually have been challenging due to the high homology between the two proteins.

Vanqua Bio Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating VQ-101, its Small Molecule GCase Activator for GBA-Parkinson’s Disease and Related Disorders

Retrieved on: 
Tuesday, April 9, 2024

CHICAGO, April 09, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced that the first patient has been dosed in a first-in-human Phase 1 clinical study evaluating VQ-101 in healthy individuals and patients with various forms of Parkinson’s disease (PD). VQ-101 is an orally administered brain-penetrant small molecule allosteric activator of the lysosomal enzyme glucocerebrosidase (GCase).

Key Points: 
  • VQ-101 is an orally administered brain-penetrant small molecule allosteric activator of the lysosomal enzyme glucocerebrosidase (GCase).
  • “VQ-101 demonstrated promising efficacy, safety, pharmacokinetics, and target engagement in preclinical studies.
  • Mutations in GBA1 are the most common genetic risk factor for PD, representing approximately 10% of patients with PD worldwide.
  • In developing VQ-101, Vanqua is adopting a precision-medicine approach that focuses initially on patients with GBA-PD, the largest genetically defined segment of PD.

Sabert Seals in Freshness and Sustainability with Compostable Pulp Produce and Protein Trays

Retrieved on: 
Tuesday, April 9, 2024

SAYREVILLE, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Sabert Corporation, a leading global manufacturer of innovative food packaging solutions, today announced the launch of its new line of Pulp Protein and Produce Trays.

Key Points: 
  • SAYREVILLE, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Sabert Corporation, a leading global manufacturer of innovative food packaging solutions, today announced the launch of its new line of Pulp Protein and Produce Trays.
  • The Pulp 2S Produce Tray caters to the growing consumer trend of hybrid cooking, blending meal planning, meal kits and ready-to-eat items.
  • Engineered with Sabert's Pulp Plus™ molded fiber blend, the Pulp Produce Tray is refrigerator safe for up to seven days.
  • For more information about Sabert's Pulp Produce and Protein Trays, please visit www.sabert.com .

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Retrieved on: 
Tuesday, April 9, 2024

SAN DIEGO, April 09, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two posters being presented today at the American Association of Cancer Research (AACR) Annual Meeting.

Key Points: 
  • The tumor microenvironment (TME) is a complex interplay of various cell types, extracellular matrix, signalling molecules and physical factors that collectively influence tumor growth.
  • Lipids play an important role in the TME, contributing to various aspects of cancer progression and therapy resistance.
  • They also further explain the compelling clinical data we have generated with NUC-7738 as a monotherapy and in combination with pembrolizumab.
  • Our translational data help us to understand these clinical observations and guide the optimal development pathway for NUC-7738.

4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity

Retrieved on: 
Tuesday, April 9, 2024

London, UK, 9 April 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that its portfolio company, Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has acquired the Contract, Manufacturing and Controls (CMC) team and site in Alachua, Florida, from Beacon Therapeutics (Beacon).

Key Points: 
  • London, UK, 9 April 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces that its portfolio company, Ascend Advanced Therapies (Ascend), an end-to-end gene therapy development partner, has acquired the Contract, Manufacturing and Controls (CMC) team and site in Alachua, Florida, from Beacon Therapeutics (Beacon).
  • The transaction brings an operational good manufacturing practice (GMP) facility, process and analytical development capabilities, and additional experts to the Ascend team.
  • This key acquisition brings Ascend its first US manufacturing site, a huge milestone for the Company.
  • The facility is highly synergistic to a growing global network of Ascend sites that has been built via critical acquisitions.

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

Retrieved on: 
Monday, April 8, 2024

REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of two peer-reviewed research papers in Nature. The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants. The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC. This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.

Key Points: 
  • The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants.
  • The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.
  • This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
  • Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), PDAC and colorectal cancer (CRC).

Wyss Institute’s AminoX project receives funding from Northpond Labs to accelerate innovation in protein-based therapeutics

Retrieved on: 
Monday, April 8, 2024

This is the fourth Wyss project selected by Northpond Labs for additional funding.

Key Points: 
  • This is the fourth Wyss project selected by Northpond Labs for additional funding.
  • The Laboratory has previously funded the Wyss’ eRNA (now being commercialized by EnPlusOne Biosciences ), SomaCode , and Lab-on-a-Molecule projects.
  • “The AminoX platform has the potential to transform our ability to develop differentiated protein-based therapeutics by significantly expanding the vocabulary of building blocks that can be incorporated into biologics at high throughput.
  • We are thrilled that the AminoX team’s journey to the market will be accelerated by this support,” said Angelika Fretzen, Ph.D., M.B.A., the Wyss Institute’s Technology Translation Director & Chief Operating Officer.